Form 4: ADC Therapeutics Director Jean-Pierre Bizzari Receives Annual Grant of Restricted Stock Units

Director Jean-Pierre Bizzari received 40,000 restricted stock units (RSUs) from ADC Therapeutics as part of the annual grant under the 2019 Equity Incentive Plan.

Summary

• Jean-Pierre Bizzari, a director of ADC Therapeutics SA, received an annual grant of 40,000 restricted stock units (RSUs) on June 13, 2024.
• The RSUs were granted under the Issuer's 2019 Equity Incentive Plan for service as a Director.
• These RSUs vest one year from the grant date, contingent upon Bizzari's continued service to the Issuer.
• Each RSU represents a contingent right to receive one share of ADC Therapeutics' common stock.
• Following the transaction, Bizzari beneficially owns 86,497 common shares.

Sentiment

Score: 7

Explanation: The document reflects a routine grant of stock units, indicating a stable and ongoing relationship between the director and the company. It's a neutral event with a slightly positive implication for alignment of interests.

Positives

• The grant of RSUs aligns the director's interests with those of the shareholders, incentivizing continued service and contribution to the company's success.
• The vesting period of one year ensures a commitment from the director to remain with the company.

Future Outlook

The RSUs will vest one year from the grant date, contingent upon the director's continued service.

Industry Context

Grants of restricted stock units to directors are a common practice in publicly traded companies to align their interests with those of shareholders and incentivize long-term value creation.

Comparison to Industry Standards

• Director compensation packages, including RSU grants, vary significantly across the pharmaceutical industry depending on company size, performance, and board structure.
• Comparing the size of this RSU grant to those of directors at similar-sized biotech companies like Seagen (now part of Pfizer) or Immunogen would provide a benchmark for assessing its relative value.
• Industry standards often tie vesting schedules to performance metrics or strategic milestones to further align director incentives with company goals.

Stakeholder Impact

• The RSU grant aligns the director's interests with those of shareholders, potentially leading to decisions that enhance shareholder value.
• The grant does not have a direct impact on employees, customers, suppliers, or creditors.

Key Dates